The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.
06-Aug-2013 - Enteris has acquired an oral drug delivery platform from Unigene Laboratories and says the excipients used can increase solubility and absorption for both peptides and small molecules.
06-Aug-2013 - Merck & Co. will close the doors on its Kenilworth, New Jersey manufacturing plant affecting 100 jobs in a continuation of its consolidation efforts.
05-Aug-2013 - Kemwell has positioned a foothold in the US with the acquisition of drug delivery research firm Cirrus Pharmaceuticals.
31-Jul-2013 - Medicines New Zealand has merged with the Vaccines Industry Association of New Zealand (VIANZ) in order to share resources and provide a single point of contact for all stakeholders.
30-Jul-2013 - Valeant says it will slash its workforce by up to 15% and consolidate some of its non-US locations following the acquisition of Bausch & Lomb.
25-Jul-2013 - Tasi Group has acquired pharmaceutical leak testing firm Sepha and plans to seek more customers overseas.
09-Jul-2013 - Teva says it will reap the benefits of changing attitudes to generic drugs in Japan as it doubles its production capacity in the country.
18-Jun-2013 - Teva has affirmed its respiratory drug delivery strategy with the purchase of MicroDose Therapeutx for a potential $165m (€123m).
05-Jun-2013 - Swedish allergy drug company Meda has denied it has been in discussions with Sun Pharma over a possible $5bn (€3.8bn) takeover.
30-May-2013 - GlaxoSmithKline has brought its vaccine development in-house with the purchase of Okairos and its supplementary technology platform.
09-Apr-2013 - Bristol-Myers Squibb says shuttering Amylin’s San Diego facilities will accelerate its diabetes R&D joint venture with AstraZeneca though approximately 300 jobs will be lost.
03-Apr-2013 - AmerisourceBergen has sold AndersonBrecon for $308m, exiting the contract packaging business in order to concentrate on its core business.
26-Mar-2013 - Shire says it is laying down a foundation into the specialty ophthalmology field following its second acquisition in a matter of weeks.
19-Mar-2013 - As the dissolution of Angel continues, its core manufacturing facility has been bought by AB Technology ensuring long term operations and rescuing 23 jobs.
18-Mar-2013 - Following last week’s shuttering of a manufacturing plant administrators have sold Angel Biomedical to new company Collbio as they start offloading CMOs assets.
14-Mar-2013 - Shire has entered the neonatology market by acquiring Premacure and a new therapy and delivery technology designed to treat infant blindness.
14-Mar-2013 - Following an analysis of its global R&D business Actavis says it will close its Maltese R&D unit at a cost of 60 jobs.
12-Mar-2013 - Patheon says the shuttering of one of Banner’s manufacturing sites is necessary in integrating the recent acquisition into its global business structure.
04-Mar-2013 - Mylan says its acquisition of Agila puts the generics company in a “leading position” in the injectables market.
01-Mar-2013 - Capsugel says the acquisition of Encap is part of its recently announced Dosage Form Solutions (DFS) strategy.
26-Feb-2013 - Following a bout of investments, the oral dose solution market has been described as “competitive” and “dynamic” by two of the major players.
20-Feb-2013 - Chemical distributor IMCD Group says acquisition of Mumbai-based Indchem will build its presence in the Indian pharmaceutical excipient sector.
19-Feb-2013 - Mylan Laboratories has purchased a new finished formulations facility in an Indian Special Economic Zone from Unichem Laboratories.
14-Feb-2013 - Merck says it will keep in-house API production capacity as it continues to evaluate its manufacturing strategy.
11-Feb-2013 - Teva says the offloading of its Californian manufacturing facility is part of cost-cutting plans designed to save $2bn (€1.5bn). in the next few years.